Data from phase III studies,GEMSTONE-301 and GEMSTONE-302, of sugemalimab for NSCLC were published in The Lancet Oncology.- EQRx Inc., and CStone Pharmaceuticals.
See-" Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase III trial"-Prof Qing Zhou, MD, Prof Ming Chen, MD ,Prof Ou Jiang, MD, et al. Published:January 14, 2022DOI:https://doi.org/10.1016/S1470-2045(21)00630-6.The Lancet Oncology.
See-"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase III clinical trial".Prof Caicun Zhou, MD ,Prof Ziping Wang, MD,Prof Yuping Sun, MD,et al. Published: 14 January ,m2022DOI:https://doi.org/10.1016/S1470-2045(21)00650-1. The Lancet Oncology.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins